These results support our previous findings,8 suggesting that the combination of tumor (ie, ERBB2 amplicon genes, proliferation, and luminal signatures) and immune-related biomarkers provide essential prognostic information to stratify patients with ERBB2/HER2-positive EBC in different groups that could benefit from different treatment strategies; some newer commercially available predictors already integrate these elements into a single assay.24 This evidence concerns the gene ERBB2 and neoplasm.